Actavis has an eye on more deals, for 'couple billion dollars' or so

Actavis CEO Brent Saunders

Actavis ($ACT), still awaiting the close of its $66 billion buyout of Allergan ($AGN), is on the lookout for more bolt-on acquisitions. As CEO Brent Saunders told Bloomberg, the company isn't up for any transformational deals in the short term, instead looking for buyouts in the "couple billion dollar" range. More

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.